利妥昔单抗治疗中度至重度非肾脏系统性红斑狼疮：EXPLORER研究的重新分析 - Suppr | 超能文献

相似文献

1

Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study.利妥昔单抗治疗中度至重度非肾脏系统性红斑狼疮：EXPLORER研究的重新分析

Ann Rheum Dis. 2019 Jul;78(7):1007-1010. doi: 10.1136/annrheumdis-2018-214833. Epub 2019 Jan 4.

2

Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.预测和预后因素对系统性红斑狼疮（SLE）利妥昔单抗治疗结局的影响：系统评价。

Semin Arthritis Rheum. 2017 Dec;47(3):384-396. doi: 10.1016/j.semarthrit.2017.04.010. Epub 2017 May 5.

3

Rituximab in Treatment of Children with Refractory Vasculitis and Systemic Lupus Erythematosus - Single Center Experience in Croatia.利妥昔单抗治疗儿童难治性血管炎和系统性红斑狼疮——克罗地亚单中心经验。

Acta Dermatovenerol Croat. 2020 Aug;28(2):63-69.

4

Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.利妥昔单抗与狼疮：现实生活中有效，对照试验中无效。对Lu等人文章的评论

Arthritis Rheum. 2009 Sep 15;61(9):1281-2. doi: 10.1002/art.24726.

5

Why, why, why de-lupus (does so badly in clinical trials).为什么，为什么，为什么狼疮治疗药物（在临床试验中表现如此糟糕）。

Expert Rev Clin Immunol. 2016;12(2):95-8. doi: 10.1586/1744666X.2016.1112270. Epub 2016 Jan 19.

6

Successful Treatment with Rituximab in a Patient with Castleman's Disease Complicated by Systemic Lupus Erythematosus and Severe Autoimmune Thrombocytopenia.利妥昔单抗成功治疗一例合并系统性红斑狼疮和严重自身免疫性血小板减少症的Castleman病患者

Chin Med J (Engl). 2015 Sep 20;128(18):2551-2. doi: 10.4103/0366-6999.164989.

7

Current role of rituximab in systemic lupus erythematosus.利妥昔单抗在系统性红斑狼疮中的当前作用。

Int J Rheum Dis. 2015 Feb;18(2):154-63. doi: 10.1111/1756-185X.12463. Epub 2014 Dec 19.

8

Rituximab in the treatment of shrinking lung syndrome in systemic lupus erythematosus.利妥昔单抗治疗系统性红斑狼疮所致的缩窄性肺综合征

Reumatol Clin. 2014 Sep-Oct;10(5):325-7. doi: 10.1016/j.reuma.2013.09.003. Epub 2013 Dec 4.

9

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.在系统性红斑狼疮患者中皮下注射贝利尤单抗序贯治疗联合一个疗程利妥昔单抗的疗效和安全性：3 期、随机、安慰剂对照 BLISS-BELIEVE 研究。

Ann Rheum Dis. 2024 Oct 21;83(11):1502-1512. doi: 10.1136/ard-2024-225686.

10

Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.利妥昔单抗在儿童期起病的系统性红斑狼疮及其他风湿性疾病中的安全性和有效性。

J Rheumatol. 2015 Mar;42(3):541-6. doi: 10.3899/jrheum.140863. Epub 2015 Jan 15.

引用本文的文献

1

CAR T-Cell Therapy for Rheumatic Diseases: What Does the Future Hold?用于治疗风湿性疾病的嵌合抗原受体T细胞疗法：未来前景如何？

BioDrugs. 2025 Jan;39(1):5-19. doi: 10.1007/s40259-024-00692-z. Epub 2024 Dec 29.

2

CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses.CaMK4在正常和自身免疫性T细胞依赖性B细胞反应过程中控制滤泡辅助性T细胞的扩增和功能。

Nat Commun. 2024 Jan 29;15(1):840. doi: 10.1038/s41467-024-45080-x.

3

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review.